| Title : Review on anti-alzheimer drug development: approaches, challenges and perspectives - Abdallah_2024_RSC.Adv_14_11057 |
| Author(s) : Abdallah AE |
| Ref : RSC Adv , 14 :11057 , 2024 |
| Abstract : Alzheimer is an irreversible progressive neurodegenerative disease that causes failure of cerebral neurons and disability of the affected person to practice normal daily life activities. There is no concrete evidence to identify the exact reason behind the disease, so several relevant hypotheses emerged, highlighting many possible therapeutic targets, such as acetylcholinesterase, cholinergic receptors, N-methyl d-aspartate receptors, phosphodiesterase, amyloid beta protein, protein phosphatase 2A, glycogen synthase kinase-3 beta, beta-secretase, gamma-secretase, alpha-secretase, serotonergic receptors, glutaminyl cyclase, tumor necrosis factor-alpha, gamma-aminobutyric acid receptors, and mitochondria. All of these targets have been involved in the design of new potential drugs. An extensive number of these drugs have been studied in clinical trials. However, only galantamine, donepezil, and rivastigmine (ChEIs), memantine (NMDA antagonist), and aducanumab and lecanemab (selective anti-Abeta monoclonal antibodies) have been approved for AD treatment. Many drugs failed in the clinical trials to such an extent that questions have been posed about the significance of some of the aforementioned targets. On the contrary, the data of other drugs were promising and shed light on the significance of their targets for the development of new potent anti-alzheimer drugs. |
| ESTHER : Abdallah_2024_RSC.Adv_14_11057 |
| PubMedSearch : Abdallah_2024_RSC.Adv_14_11057 |
| PubMedID: 38586442 |
Abdallah AE (2024)
Review on anti-alzheimer drug development: approaches, challenges and perspectives
RSC Adv
14 :11057
Abdallah AE (2024)
RSC Adv
14 :11057